Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Oxford BioDynamics director Diggle raises stake to 15%

Thu, 18th Nov 2021 16:20

Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Non-Executive Director Stephen Diggle buys 2.5 million shares via Vulpes Life Sciences Fund and Vulpes Testudo Fund at average 45.5 pence, worth GBP1.1 million, on Tuesday. Diggle now is interested in 14.7 million shares, a 14.7% stake.

Current stock price: 43.30p, up 0.7% on Thursday

Year-to-date change: down 48%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
11 Jun 2024 16:01

UK earnings, trading statements calendar - next 7 days

4 Jun 2024 10:28

Oxford BioDynamics develops canine cancer test with 89% accuracy

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced the development of a canine cancer diagnostic test based on its EpiSwitch non-invasive p...

23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

21 May 2024 14:06

Oxford BioDynamics to provide tests to largest UK charitable hospital

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.